Antidepressant Safe in Narrow Angle Glaucoma
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are the safest antidepressants for patients with narrow-angle glaucoma, as they are not associated with increased glaucoma risk and may actually lower intraocular pressure.
Primary Recommendation
SSRIs and SNRIs should be your first-line antidepressants in patients with narrow-angle glaucoma 1, 2. A 2021 comprehensive review found that these agents have "the best evidence as having no association with glaucoma" 1. More compellingly, a 2018 meta-analysis of 801,754 patients demonstrated that SSRI use was not associated with higher glaucoma risk (pooled adjusted OR = 0.956,95% CI = 0.807-1.133, p = 0.604) and was actually associated with significantly lower intraocular pressure 2.
Antidepressants to AVOID
Tricyclic antidepressants (TCAs) should be avoided in patients with narrow-angle glaucoma 1. These medications have anticholinergic properties that cause pupillary dilation, which can precipitate acute angle-closure attacks in anatomically predisposed eyes with pre-existing narrow angles 3.
Mechanism and Clinical Context
The safety profile of SSRIs/SNRIs relates to their lack of anticholinergic activity. In contrast, medications with anticholinergic or adrenergic properties trigger classic pupillary-block acute angle-closure glaucoma by causing mydriasis (pupil dilation), which bunches the peripheral iris against the trabecular meshwork in eyes with narrow angles 3.
Important Caveats
Monitor for rare paradoxical reactions: While SSRIs are generally safe, isolated case reports exist of acute glaucoma attacks during SSRI treatment 4. The mechanism is unclear and causality uncertain, but ophthalmologic consultation should be considered if visual symptoms develop.
Timing matters: Most medication-induced angle-closure events occur shortly after treatment initiation or dose escalation 3.
Patient education: Brief counseling on warning symptoms (sudden eye pain, blurred vision, halos around lights, headache) represents a pragmatic risk-reduction strategy 3.
Practical Algorithm
- First choice: SSRI (e.g., sertraline, escitalopram, fluoxetine) or SNRI (e.g., venlafaxine, duloxetine)
- Avoid completely: Tricyclic antidepressants (amitriptyline, imipramine, nortriptyline)
- Monitor closely: Any new visual symptoms warrant immediate ophthalmologic evaluation
- Consider prophylaxis: If the patient has not had laser peripheral iridotomy, discuss with ophthalmology whether this preventive procedure is indicated before starting any antidepressant